<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00957684</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-2093-301</org_study_id>
    <nct_id>NCT00957684</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures</brief_title>
  <official_title>Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a phase III 4-part study in multiple centres. Part I was a 26-week parallel-group,
      randomised, placebo-controlled period (8 weeks single-blind placebo baseline, 2 weeks
      double-blind titration, 12 weeks maintenance, and 4 weeks tapering off). After completing the
      baseline period, patients were randomised in a 1:1:1:1 ratio to 1 of 3 ESL dose levels or to
      placebo. Part II was a 1-year open-label extension for patients who had completed Part I. The
      starting dose was 800 mg once daily and could be titrated up or down at 400-mg intervals
      between 400 and 1200 mg. Part III was an additional 1-year open-label extension for patients
      who had completed Part II, had participated in the post-Part II study extension, which
      allowed patients to continue treatment with ESL, or had continued to take ESL in a
      compassionate use program. ESL starting doses were the same as received at the end of Part
      II, during post-Part II study extension, or under compassionate use, and could be titrated up
      or down at 400-mg intervals between 400 and 1200 mg once daily. Part IV was a study extension
      to allow patients to continue ESL treatment after the end of Part III until marketing
      authorisation or discontinuation of clinical development.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Duration of Treatment: The duration of Part I was 26 weeks: 8 weeks of placebo run-in, 2
      weeks of dose titration, 12 weeks of maintenance, and 4 weeks of tapering-off period. The
      duration of Part II was 1 year. The duration of Part III was planned to be 1 year (some
      patients were treated for &gt;1 year). The duration of Part IV was &gt;3 years (patients could
      continue treatment with ESL until market availability).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part I: Seizure Frequency</measure>
    <time_frame>12-week maintenance period</time_frame>
    <description>The primary efficacy endpoint is the natural log transformation of the seizure frequency per 4 weeks. The primary efficacy analysis was based on the intention-to-treat (ITT) population. Efficacy analyses were performed chiefly using data from the 12-week maintenance period in Part I of the study. The primary efficacy variable is the ln transformation of the seizure frequency per 4 weeks. Seizure frequency was compared between each active treatment group and the placebo group using an ANCOVA that models seizure frequency as a function of baseline seizure frequency and treatment.to a &quot;frequency per 4 weeks&quot; basis</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">402</enrollment>
  <condition>Refractory Partial Epilepsy</condition>
  <arm_group>
    <arm_group_label>ESL 400 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESL was supplied in 400-mg and 800-mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESL 800 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESL was supplied in 400-mg and 800-mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESL 1200 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESL was supplied in 400-mg and 800-mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESL - PART II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During Part II of the study all patients received Eslicarbazepine Acetate (ESL), including those who had been treated with placebo during Part I. ESL was supplied as scored 800 mg tablets; once daily administration by oral route.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eslicarbazepine acetate</intervention_name>
    <description>once-daily oral tablet</description>
    <arm_group_label>ESL 400 mg once daily</arm_group_label>
    <arm_group_label>ESL 800 mg once daily</arm_group_label>
    <arm_group_label>ESL 1200 mg once daily</arm_group_label>
    <arm_group_label>ESL - PART II</arm_group_label>
    <other_name>Zebinix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>once daily placebo comparator</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent signed by patient

          -  aged 18 years or more

          -  documented diagnosis of simple or complex partial seizures with or without secondary
             generalisation since at least 12 months prior to screening

          -  at least 4 partial seizures in each 4 week period during the last 8 weeks prior to
             screening, currently treated with 1 or 2 AEDs (any except oxcarbazepine and
             felbamate), in a stable dose regimen during at least 2 months prior to screening
             (patients using vigabatrin should have been on this medication for at least 1 year
             with no deficit in visual field identified)

          -  excepting epilepsy, patient is judged to be in general good health based on medical
             history, physical examination and laboratory tests

          -  post-menopausal or otherwise incapable of becoming pregnant by reason of surgery or
             tubal ligation; in case of woman of childbearing potential, patient must present a
             serum beta-hCG test consistent with a non-gravid state and agree to remain abstinent
             or use reliable contraception (oral contraception should be combined with a barrier
             method)

        Exclusion Criteria:

          -  only simple partial seizures with no motor symptomatology (classified as A2-4
             according to the International Classification of Epileptic Seizures) that are not
             video-EEG documented

          -  primarily generalised epilepsy

          -  known rapid progressive neurological disorder; history of status epilepticus or
             cluster seizures (i.e., 3 or more seizures within 30 minutes) within the 3 months
             prior to screening

          -  seizures of psychogenic origin within the last 2 years

          -  history of schizophrenia or suicide attempt

          -  currently on or with exposure to felbamate or oxcarbazepine more within one month of
             screening

          -  using benzodiazepines on more than on an occasional basis (except when used
             chronically as AED)

          -  previous use of ESL or participation in a clinical study with ESL

          -  known hypersensitivity to carbamazepine, oxcarbazepine or chemically related
             substances

          -  history of abuse of alcohol, drugs or medications within the last 2 years

          -  uncontrolled cardiac, renal, hepatic, endocrine, gastrointestinal, metabolic,
             haematological or oncology disorder

          -  second or third-degree atrioventricular blockade not corrected with a pacemaker

          -  relevant clinical laboratory abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Christian Elger</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Epileptology, Friedrich Wilhelms University Bonn</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Peter Halasz</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Psychiatry and Neurology, Budapest, Hungary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bial - Portela &amp; Cª, S.A.</name>
      <address>
        <city>S. Mamede do Coronado</city>
        <zip>4745-457</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Hungary</country>
  </removed_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2009</study_first_submitted>
  <study_first_submitted_qc>August 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2009</study_first_posted>
  <results_first_submitted>March 26, 2013</results_first_submitted>
  <results_first_submitted_qc>August 2, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 10, 2013</results_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory</keyword>
  <keyword>partial</keyword>
  <keyword>epilepsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eslicarbazepine acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study initiation date: 15/July/2004(first visit of the first patient) Study Part I completion date: 09/November/2005(last Part I visit of the last patient) Study Part II initiation date: 11 JAN 2005 (first Part II visit of the first patient) Study Part II completion date: 04 JAN 2007 (last Part II visit of the last patient)</recruitment_details>
      <pre_assignment_details>After completing the baseline period, patients were randomised in a 1:1:1:1 ratio to 1 of the 3 Eslicarbazepine acetate (ESL) dose levels or to placebo.
Part II was a 1-year open-label extension for patients who had completed Part I</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ESL 1200 mg Once Daily</title>
          <description>eslicarbazepine acetate : once-daily oral tablet</description>
        </group>
        <group group_id="P2">
          <title>ESL 800 mg Once Daily</title>
          <description>eslicarbazepine acetate : once-daily oral tablet</description>
        </group>
        <group group_id="P3">
          <title>ESL 400 mg Once Daily</title>
          <description>eslicarbazepine acetate : once-daily oral tablet</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>placebo : once daily placebo comparator</description>
        </group>
        <group group_id="P5">
          <title>ESL - Part II</title>
          <description>During Part II of the study all patients received ESL, including those who had been treated with placebo during Part I. The duration of treatment during Part II was one year for all patients completing the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>PART I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="100"/>
                <participants group_id="P4" count="102"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomised (Safety Population)</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="100"/>
                <participants group_id="P4" count="102"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intention-to-treat (ITT) Population</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="99"/>
                <participants group_id="P4" count="102"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per-protocol (PP)Population</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="86"/>
                <participants group_id="P3" count="94"/>
                <participants group_id="P4" count="91"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="90"/>
                <participants group_id="P4" count="84"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>PART II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="314"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Patients Entered Part II</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="314"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="239"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="75"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ESL 1200 mg</title>
          <description>400-mg + 800-mg; once daily administration by oral route</description>
        </group>
        <group group_id="B2">
          <title>ESL 800 mg</title>
          <description>800-mg; once daily administration by oral route</description>
        </group>
        <group group_id="B3">
          <title>ESL 400 mg</title>
          <description>400-mg; once daily administration by oral route</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo tablets; once daily administration by oral route</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
            <count group_id="B2" value="98"/>
            <count group_id="B3" value="100"/>
            <count group_id="B4" value="102"/>
            <count group_id="B5" value="402"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="102"/>
                    <measurement group_id="B5" value="399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part I: Seizure Frequency</title>
        <description>The primary efficacy endpoint is the natural log transformation of the seizure frequency per 4 weeks. The primary efficacy analysis was based on the intention-to-treat (ITT) population. Efficacy analyses were performed chiefly using data from the 12-week maintenance period in Part I of the study. The primary efficacy variable is the ln transformation of the seizure frequency per 4 weeks. Seizure frequency was compared between each active treatment group and the placebo group using an ANCOVA that models seizure frequency as a function of baseline seizure frequency and treatment.to a “frequency per 4 weeks” basis</description>
        <time_frame>12-week maintenance period</time_frame>
        <population>The primary efficacy analysis was based on the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets matching the 400-mg and 800-mg active substance tablets were supplied; once daily administration by oral route.</description>
          </group>
          <group group_id="O2">
            <title>ESL 400 mg</title>
            <description>ESL was supplied in 400-mg tablets; once daily administration by oral route.</description>
          </group>
          <group group_id="O3">
            <title>ESL 800 mg</title>
            <description>ESL was supplied in 800-mg tablets; once daily administration by oral route.</description>
          </group>
          <group group_id="O4">
            <title>ESL 1200 mg</title>
            <description>ESL was supplied in 400-mg and 800-mg tablets; once daily administration by oral route.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Seizure Frequency</title>
          <description>The primary efficacy endpoint is the natural log transformation of the seizure frequency per 4 weeks. The primary efficacy analysis was based on the intention-to-treat (ITT) population. Efficacy analyses were performed chiefly using data from the 12-week maintenance period in Part I of the study. The primary efficacy variable is the ln transformation of the seizure frequency per 4 weeks. Seizure frequency was compared between each active treatment group and the placebo group using an ANCOVA that models seizure frequency as a function of baseline seizure frequency and treatment.to a “frequency per 4 weeks” basis</description>
          <population>The primary efficacy analysis was based on the ITT population.</population>
          <units>ln (Seizures) per 4 weeks</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="98"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.64" spread="0.0563" lower_limit="6.78" upper_limit="8.58"/>
                    <measurement group_id="O2" value="6.73" spread="0.0563" lower_limit="5.93" upper_limit="7.60"/>
                    <measurement group_id="O3" value="5.66" spread="0.0558" lower_limit="4.92" upper_limit="6.45"/>
                    <measurement group_id="O4" value="5.35" lower_limit="4.63" upper_limit="6.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>26-week</time_frame>
      <desc>Safety endpoints included Adverse events (AEs), clinical laboratory tests (haematology, coagulation, biochemistry, thyroid function, and urinalysis), vital signs and weight, electrocardiogram, and blood trough levels of concomitant Anti-epileptic drug (AEDs).</desc>
      <group_list>
        <group group_id="E1">
          <title>ESL 1200 mg Once Daily</title>
          <description>eslicarbazepine acetate : once-daily oral tablet</description>
        </group>
        <group group_id="E2">
          <title>ESL 400 mg Once Daily</title>
          <description>eslicarbazepine acetate : once-daily oral tablet</description>
        </group>
        <group group_id="E3">
          <title>ESL 800 mg Once Daily</title>
          <description>eslicarbazepine acetate : once-daily oral tablet</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>placebo : once daily placebo comparator</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma—glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Exanthem</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="102"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="98"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="102"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research Section</name_or_title>
      <organization>BIAL - Portela &amp; Ca, SA</organization>
      <phone>351 22 986 6100</phone>
      <email>clinical.trials@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

